SARS-CoV-2 serology in HIV PrEP users during the COVID-19 pandemic.

SARS-CoV-2 serology in HIV PrEP users during the COVID-19 pandemic. - PrEP-Co

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00022403

Enrollment

300

Registered

2020-07-15

Start date

2020-05-18

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV-PrEP STD none

Interventions

Group 1: Performance of SARS-CoV-2 serology

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - MSM reporting PrEP-use within last 90 months prior to screening visit - Written informed consent. - Age =18 years.

Exclusion criteria

Exclusion criteria: Persons with any kind of dependency on the investigator.

Design outcomes

Primary

Measure	Time frame
Seroconversion rate pointprevalence of SARS-CoV-2 antibody during the time of this study.	—

Secondary

Measure	Time frame
- Pointprevalence of SARS-CoV-2 antibodies at baseline. - Pointprevalence of SARS-CoV-2 antibodies at follow-up visits. - correlation of the seroprevalence and/or seroconversion of SARS-CoV-2 positivity with sexual behaviour and other sexual transmitted diseases (STDs), such as syphilis, N. gonococcae, M. genitalium, C.trachomatis or HIV.	—

Countries

Germany

Contacts

Public ContactChristoph Spinner

IZAR

izar@mri.tum.de089/41402451

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 11, 2026